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Spinocerebellar ataxia type 23 is caused by mutations in PDYN, which encodes the opioid neuropeptide precursor protein,
prodynorphin. Prodynorphin is processed into the opioid peptides, a-neoendorphin, and dynorphins A and B, that normally
exhibit opioid-receptor mediated actions in pain signalling and addiction. Dynorphin A is likely a mutational hotspot for spino-
cerebellar ataxia type 23 mutations, and in vitro data suggested that dynorphin A mutations lead to persistently elevated mutant
peptide levels that are cytotoxic and may thus play a crucial role in the pathogenesis of spinocerebellar ataxia type 23. To further
test this and study spinocerebellar ataxia type 23 in more detail, we generated a mouse carrying the spinocerebellar ataxia type
23 mutation R212W in PDYN. Analysis of peptide levels using a radioimmunoassay shows that these PDYNR212W mice display
markedly elevated levels of mutant dynorphin A, which are associated with climber fibre retraction and Purkinje cell loss,
visualized with immunohistochemical stainings. The PDYNR212W mice reproduced many of the clinical features of spinocerebellar
ataxia type 23, with gait deficits starting at 3 months of age revealed by footprint pattern analysis, and progressive loss of motor
coordination and balance at the age of 12 months demonstrated by declining performances on the accelerating Rotarod.
The pathologically elevated mutant dynorphin A levels in the cerebellum coincided with transcriptionally dysregulated ionotropic
and metabotropic glutamate receptors and glutamate transporters, and altered neuronal excitability. In conclusion, the PDYNR212W
mouse is the first animal model of spinocerebellar ataxia type 23 and our work indicates that the elevated mutant dynorphin
A peptide levels are likely responsible for the initiation and progression of the disease, affecting glutamatergic signalling, neuronal
excitability, and motor performance. Our novel mouse model defines a critical role for opioid neuropeptides in spinocerebellar
ataxia, and suggests that restoring the elevated mutant neuropeptide levels can be explored as a therapeutic intervention.
1 Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
2 Division of Biological Research on Drug Dependence, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala,
Sweden
3 Department of Medical Physiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
4 Department of Pathology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
5 Department of Paediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA
6 Department of Cell Biology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
7 Department of Paediatrics, Molecular Genetics Section, University of Groningen, University Medical Centre Groningen,
Groningen, The Netherlands
doi:10.1093/brain/awv195 BRAIN 2015: 138; 2537–2552 | 2537
Received December 22, 2014. Revised May 7, 2015. Accepted May 27, 2015. Advance Access publication July 13, 2015
 The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Correspondence to: D. S. Verbeek,
Department of Genetics, PO box 30001,
9700 RB Groningen, The Netherlands
E-mail: d.s.verbeek@umcg.nl
Keywords: prodynorphin; opioid; glutamate; neurodegeneration; spinocerebellar ataxia
Abbreviations: AMPA-R = -amino-3-hydroxy-5-methylisoxazole-4-propionate receptor; NMDA-R = N-methyl-D-aspartate
receptor; SCA = spinocerebellar ataxia; Sim/Crus = lobules simplex and CrusI and CrusII ansiform lobules; vGlut2 = vesicular
glutamate transporter 2
Introduction
PDYN is the precursor protein for the opioid peptides
-neoendorphin, dynorphin A, and dynorphin B. The
actions of these neuropeptides are mediated via the
kappa-opioid receptor (encoded by OPRK1) (Akil et al.,
1984; Merg et al., 2006). Dynorphins regulate pain, sub-
stance dependence, and stress-induced responses via opioid-
receptor signalling (Hauser et al., 2005; Chavkin, 2013).
However, dynorphin A can also exhibit non-opioid-
mediated neurotoxic effects, as elevated peptide levels
cause allodynia, paralysis and neuronal loss in the spinal
cord of mice, which could not be blocked by an opioid
antagonist (Herman et al., 1980; Walker et al., 1982;
Hauser et al., 2005). Dynorphin A was shown to cause
pronounced cell death that was dependent on the presence
of NMDA-Rs (N-methyl D-aspartate receptors) (Tan-No
et al., 2001). Additional neurotoxic mechanisms of dynor-
phins may be mediated via numerous receptors and/ or
channels such as AMPA-Rs (-amino-3-hydroxy-5-methyli-
soxazole-4-propionate receptors) (Singh et al., 2003) or
ASIC1a (acid-sensing ion 1a) channels (Sherwood and
Askwith, 2009).
Mutations in PDYN were shown to cause spinocerebellar
ataxia type 23 (SCA23), a slowly progressive, autosomal
dominant neurodegenerative disorder (Bakalkin et al.,
2010). SCA23 patients suffer from relatively slowly pro-
gressive impairment of their motor coordination, and a
fairly pure cerebellar ataxia due to Purkinje cell death in
the cerebellum (Verbeek et al., 2004). The majority of
SCA23 mutations located in the highly conserved dynor-
phin A-coding region lead to enhanced levels of mutant
dynorphin A in cells, either due to higher peptide produc-
tion or increased peptide stability (Bakalkin et al., 2010).
These mutant dynorphin A peptides displayed neurotoxic
properties in cultured striatal neurons (Bakalkin et al.,
2010), and induce pathological pain when injected into
mice in femtomolar doses (Watanabe et al., 2012).
Although the mechanism is unclear, recent studies indicate
that these mutant peptides interact with and penetrate
cellular membranes in vitro, and thus lead to cell death
(Madani et al., 2011; Bjo¨rnera˚s et al., 2013). Increased
expression of PDYN and its neuropeptides have also
been implicated in age-related decline of cognition and
memory (Kotz et al., 2004; Me´nard et al., 2013).
Furthermore, elevated dynorphin A levels have been
linked to the pathology of Alzheimer’s disease (Yakovleva
et al., 2007), supporting a crucial role for elevated opioid
neuropeptides levels in the aetiology of neurodegenerative
disorders.
To reveal the causality between mutations in PDYN and
SCA23, we generated transgenic mice ubiquitously express-
ing wild-type PDYN (PDYNWT) or SCA23-mutant PDYN-
R212W (PDYNR212W) and examined whether mutant
dynorphin A may impair motor performance and induce




All animal experiments were performed according to the
guidelines of the University of Groningen, The Netherlands,
and the Mayo Clinic College of Medicine, Rochester,
Minnesota, USA. The experimental protocols were approved
by the Animal Welfare Committee of the University of
Groningen. All efforts were made to reduce the number of
animals and minimize their suffering. To generate transgenic
mice expressing wild-type (WT) PDYN or SCA23-mutant
PDYN-R212W under Cre-recombinase control, the PDYN
cDNA was cloned into the pCALL2 plasmid downstream of
a neomycin-resistance gene and transcription stop signal
(three tandemly arranged polyadenylation sites) flanked by
loxP sites (van Ree et al., 2010). Embryonic stem cell electro-
poration and clone selection was performed as described
previously (van Ree et al., 2010; Baker et al., 2013). The
blastocyst injections were performed at the Mayo Clinic
College of Medicine. The genotypes were assessed by PCR
using the following primers: PDYN-For 5’-TAGCAGTGGCG
TTCATTTTG-3’ and PDYN-Rev 5’-TCTGAGCTCCTCTTGG
GGTA-3’; loxP-For 5’-TCACTGCATTCTAGTTGTGGT-3’,
and loxP-Rev 5’-CTTATCGATACCGTCGACCT-3’.
All mice used for the experiments had a mixed 129Sv/
E  C57Bl/6 genetic background, and wild-type littermates
were used as controls. Four independent cohorts (n = 10–12)
of PDYNWT and PDYNR212W, and littermate controls were
aged for 3, 6, 9 and 12 months. Each cohort contained
equal numbers of male and female mice, and the mice were
of the indicated age. In addition to PDYN, transgenic mice
also ubiquitously express enhanced green fluorescent protein
(EGFP).
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Reverse transcription PCR and
quantitative real-time PCR
Total RNA was isolated from snap-frozen mouse cerebella
using TRIzol reagent (Life Technologies, Invitrogen).
Complementary DNA was generated using oligo-d(T) primers
and RevertAid
TM
cDNA Kit (Thermo-Scientific, Fermentas).
Quantitative real-time expression analysis was performed
using SYBR Green Mix (Life Technologies, Applied
Biosystems) on the TaqMan ABI7900HT PCR system (Life
Technologies, Applied Biosystems) using the Standard Curve
Quantification method and Gapdh and Ppia as reference
genes. The list of primers used is given in Supplementary
Table 1. All procedures were performed according to the
manufacturers’ protocols.
Protein extraction and western
blotting
Proteins were isolated from snap-frozen mouse organs. Organs
were homogenized in ice-cold isolation buffer [1% Triton
TM
X-100 (Sigma) in 10mM Tris-HEPES, pH7.6] supplemented
with a complete protease inhibitor cocktail (Roche) and
50mM dithiothreitol. Samples were centrifuged for 15min at
10 000 rpm, and protein concentrations were determined
using the Pierce BCA Protein Assay Kit (Thermo Scientific),
2 Novex Tricine SDS sample buffer (Life Technologies)
was added to the protein lysates and equal amounts were
loaded on sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) gels. After electrophoresis, the proteins
were transferred to polyvinylidene difluoride (PVDF) mem-
brane (Life Technologies) and blocked with 5% non-fat milk
in Tris-buffered saline (TBS)-Tween. The blots were analysed
with primary antibodies against human PDYN (rabbit, 1:500),
dynorphin A (rabbit, 1:300, Abcam), vesicular glutamate
transporter 2 (vGlut2; rabbit, 1:1000, Synaptic Systems),
EAAT4 (rabbit, 1:500, Alpha Diagnostics) or Calbindin
(mouse, 1:500, Abcam). Secondary antibodies were conjugated
with horseradish peroxidase (goat, 1:10 000, Jackson
ImmunoResearch Laboratories). Densitometric analysis was
performed using Fiji software (National Institutes of Health,
USA, http://fiji.sc/). Protein bands were normalized against
tubulin bands of the same sample.
Radioimmunoassay
The radioimmunoassay procedure was described elsewhere
(Christensson-Nylander et al., 1985; Yakovleva et al., 2006).
Briefly, tissue samples were extracted in 1 M acetic acid, pep-
tide fractions were isolated by SP Sephadex ion exchange
C-25 chromatography, and peptides were analysed by
radioimmunoassay.
Histology, immunofluorescent stain-
ings, silver stainings and microscopy
For immunofluorescent stainings, brains were dissected and
fixed overnight in 15% picric acid, 4% paraformaldehyde
and 0.05% glutaraldehyde in 0.1 M phosphate buffer. After
fixation, brains were cryopreserved in 10% and 20% sucrose
solutions in phosphate buffer overnight, and then frozen on
dry ice. Sectioning was performed on an HM550 Microm
cryostat (Thermo Scientific). Cerebella were cut into eight
series of 30-mm thick coronal sections. All stainings were per-
formed free floating. For overall morphology studies, sections
were stained with 1% Toluidine Blue (Sigma-Aldrich) for
2min, washed with water, and mounted in Faramount mount-
ing medium (Dako). For fluorescent staining, sections were
blocked with 3% normal donkey serum (Jackson
ImmunoResearch Laboratories) for 30min, after which antigen
retrieval was carried out in 10mM citric acid buffer (pH 6.0)
at 90C for 20min. Sections were washed in TBS, alternated
with TBS with 1% Tween for permeabilization. Sections were
incubated with primary antibody overnight at 4C and subse-
quently with secondary antibodies for 1 h at room tempera-
ture, followed by Sudan Black B incubation to eliminate
autofluorescence and transgenic GFP fluorescence (0.1% in
70% ethanol; Sigma-Aldrich) (Supplementary Fig. 1A–F),
washing with phosphate buffer + 0.02% Tween, and mount-
ing (BrightMount mounting medium). The primary antibodies
used were: anti-human PDYN (rabbit, 1:300, Yakovleva et al.,
2006) anti-dynorphin A (rabbit, 1:300, Abcam), anti-vGlut2
(rabbit, 1:1000, Synaptic Systems), anti-EAAT4 (rabbit,
1:500, Alpha Diagnostics) and anti-Calbindin (mouse, 1:500,
Abcam). Secondary anti-rabbit antibodies were conjugated
with Alexa Fluor 488 and anti-mouse antibodies with Cy3
(both: donkey, 1:250, Jackson ImmunoResearch
Laboratories).
For silver stainings, brain samples were dehydrated with a
graded ethanol series, followed by xylene and paraffination.
Paraffin sections were cut at a thickness of 5 mm. After subse-
quent deparaffination and rehydration, the cerebellar slides
were placed in a 20% AgNO3 solution for 20min at 60
C.
After rinsing in distilled water, the slides were placed in a
solution of 10% AgNO3 (to which ammonia was added
until the precipitate was dissolved) + 1ml of 25% sodium car-
bonate solution. The solution was stirred while drops of 3.7%
formalin were added until the slides stained golden brown.
After being rinsed in distilled water, the slides were placed in
5% sodium thiosulphate solution for 2min. Then the slides
were rinsed again, followed by dehydration, xylene, and
mounting. These slides were evaluated for the formation of
‘torpedoes’ (indicating axonal damage of Purkinje cells) and
‘empty baskets’ (indicating complete loss of individual
Purkinje cells).
Sections were imaged using an AxioObserver Z1 fluores-
cence microscope (Zeiss) and Leica TCS SP8 confocal micro-
scope, and the images were analysed using the ImageScope
(Aperio e-pathology solutions, http://www.aperio.com) and
Fiji software (National Institutes of Health, http://fiji.sc/).
Motor performance analyses
Footprint patterns were analysed using a runway
(80 cm  10.5 cm wide) with white paper on the bottom.
Mouse paws were painted with non-toxic, water-soluble ink
(black for hind paws and magenta for front paws; Liquitex).
Five consecutive strides were measured for each animal
(Brooks and Dunnett, 2009). To assess motor performance
the accelerating rotarod test was used (3-cm diameter rotating
cylinder; IITC). The training session contained three runs
at a stable 20 rpm at Day 1, followed by two training days
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(three runs per day) at accelerating speed (from 4 to 30 rpm
within 180 s, running 600 s in total). The experiment was per-
formed on Day 4, identical to the exercise on Days 2 and 3.
The minimal interval time in between the runs was 15min
(Brooks and Dunnett, 2009). All tests were performed without
genotype information and scored and analysed by two inde-
pendent researchers.
Cerebellar examinations: Purkinje
cell count, molecular layer thickness
and climbing fibre distribution
Purkinje cells were counted and averaged over 100mm and the
climbing fibre distribution was quantified by measuring the
height of the vGlut2 staining in the molecular layer relative
to the calbindin staining in the same region. The Purkinje cell
length was measured as the distance from the top of Purkinje
cell soma to the tip of Purkinje cell dendrite, and the climbing
fibre distribution in the molecular layer was measured from the
top of Purkinje cell soma to the tip of climbing fibre arbour.
In addition, the molecular layer thickness was measured. For
molecular layer thickness and climbing fibre distribution, at
least 10 measurements per section were taken in specific cere-
bellar regions. One series of cerebellar sections per animal and
two animals per genotype (controls, PDYNWT and
PDYNR212W) were used for one staining. Full cerebellar
regions including cerebellar lobules II, III, IV/V, VI, IX and
X, the paramedian lobule, paraflocculus, flocculus and
simplex and CrusI and CrusII ansiform lobules (Sim/Crus)
were present in different sections and two to five sections
were analysed per region.
Cerebellar primary cultures
Cerebella of postnatal Day 5 pups were dissected and were
kept on ice in supplemented PBS (0.3% bovine serum albumin
and 0.6% glucose) after removal of the meninges. After tryp-
sinization, cerebella were disaggregated in Dulbecco’s modified
Eagle medium supplemented with 10% foetal bovine
serum (FBS), 0.25% penicillin/streptomycin and DNase I
(Sigma-Aldrich), with a succession of pipettes, decreasing in
size. Cells were then counted and 200000 cells were
seeded onto poly-D-lysine/laminin coated glass coverslips in
24-wells plates, in Neurobasal medium (Life Technologies,
Gibco), supplemented with 0.5% FBS, 0.25% glutamine,
0.25% penicillin/streptomycin, and B27 (Life Technologies,
Gibco). After 24 h of culturing, inhibitor Ara-C
(Sigma-Aldrich) was added to the culture medium to decrease
glial cell growth. Neurons were cultured for 10 days before
experiments were conducted.
Immunocytochemistry
Cerebellar neurons were fixed in 4% paraformaldehyde for
10min and washed with PBS. Blocking and permeabilization
was performed with 5% normal donkey serum (Jackson
ImmunoResearch Laboratories) and 0.1% Triton
(Sigma-Aldrich) in PBS for 1 h. Neurons were incubated with
primary antibodies overnight at 4C, and for 1 h with second-
ary antibodies at room temperature. All antibodies were
diluted in blocking solution, and the primary antibodies used
were anti-human PDYN (rabbit, 1:100; Yakovleva et al.,
2006), anti-dynorphin A (rabbit, 1:100, Abcam) and anti-b3
tubulin (mouse, 1:100, Santa Cruz Biotechnology). Secondary
anti-rabbit antibodies were conjugated with Alexa Fluor 488
and anti-mouse antibodies with Cy3 (both: donkey, 1:250,
Jackson ImmunoResearch Laboratories).
Neurons were imaged using a Leica TCS SP8 confocal
microscope, and the images were analysed using Fiji software
(National Institutes of Health, http://fiji.sc/).
Electrophysiological recordings
The cerebellar neurons cultured on the poly-D-lysine/laminin-
coated coverslips were placed in a measuring chamber attached
to an Axioskop 2 FS microscope (Zeiss). Membrane currents
and voltages were measured using an Axopatch 200 B ampli-
fier (Axon Instruments), using the whole-cell patch clamp tech-
nique. Pipettes were pulled from borosilicate glass (Clarke) and
were filled with a solution containing: KCl 140mM, HEPES
10mM, EGTA 10mM, MgCl2 1mM, CaCl2 1mM, Na2ATP
2mM (280–290 mOsm). The bathing solution contained NaCl
140mM, KCl 4mM, glucose 10mM, CaCl2 2mM, HEPES
1.2mM and MgCl2 1mM (mOsm 330). The pH of all solu-
tions was adjusted to 7.40. When used with these solutions,
the pipettes had initial resistances of 5–8 M. Membrane cur-
rents were recorded at room temperature (20–22C) with the
amplifier in voltage clamp mode.
Currents were low-pass filtered at 5 kHz and sampled at
50 kHz using a Digidata 1320 AD converter (Axon
Instruments). Pipette capacitance and whole cell resistance
were compensated by 80–85%. After measuring the membrane
currents, the amplifier was switched to current clamp mode.
Following measurement of the resting membrane potential, the
membrane potential was set to 50mV using steady injected
current through the patch pipette. Input resistance was mea-
sured using small depolarizing current steps. The cell was acti-
vated with a 500ms pulse of depolarizing current. Voltage
clamp step protocols were generated and data was analysed
using Pclamp software (Axon Instruments).
Statistical analysis
All data was normalized against 3-month control data and
expressed as mean  standard error of the mean (SEM),
unless stated otherwise. Two-way ANOVA was used to deter-
mine the significance of the observed differences between the
genotypes, and over time, unless stated otherwise (P5 0.05 is
considered statistically significant).
Results
Expression of SCA23-mutant PDYN-
R212W leads to elevated levels of
cerebellar mutant dynorphin A
Previous studies have shown that the SCA23 mutation,
R212W, has the strongest effects on dynorphin A levels
in cell models compared to other mutations (Bakalkin
et al., 2010). In addition, R212W induces the strongest
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non-opioid nociceptive activity upon injection of dynorphin
A into mice (Watanabe et al., 2012). To examine the causal
role of mutant PDYN-R212W in the pathology of SCA23,
we ubiquitously expressed PDYN-wt or PDYN-R212W by
crossing (PDYNWT)flox/flox and (PDYNR212W)flox/flox mice
with hypoxanthine-guanine phosphoribosyl transferase-
Cre (HPRT-Cre) mice (Nichol et al., 2011) (Fig. 1A).
Heterozygous PDYNWT and PDYNR212W mice were born
at the expected Mendelian frequency, were fertile, appeared
healthy, and displayed body weight that was indistinguish-
able from control littermates (data not shown). Transgenic
PDYN mRNA expression was equally high in the cerebella
of PDYNWT and PDYNR212W mice at 3 months of age (Fig.
1B), which significantly decreased in PDYNWT mice but not
in PDYNR212W mice at 12 months of age (Supplementary
Fig. 2A). Transgenic PDYN wild-type or R212W expression
did not affect endogenous Pdyn mRNA expression at 3
months of age (Fig. 1C), whereas clearly reduced Pdyn ex-
pression was observed in PDYNR212W mice at 12 months of
age (Supplementary Fig. 2B). This led to approximately
equal PDYN/Pdyn mRNA levels in both models at 3 and
12 months of age. Both PDYNWT and PDYNR212W mice
Figure 1 PDYN-R212Wexpression leads to elevated mutant dynorphin A levels in the cerebellum of PDYNR212W mice. (A) The
transgene cassette contained the full PDYN cDNA downstream of two loxP sites flanking a transcription STOP signal of three consecutively
arranged polyadenylation sites. (PDYNWT)flox/flox and (PDYNR212W)flox/flox mice are crossed with HPRT-cre mice to ubiquitously express the PDYN
transgene. (B) PDYN mRNA expression levels in the cerebella of 3-month-old PDYNWT, PDYNR212W and littermate control mice (control),
normalized against 3-month-old PDYNWT mice revealed by real-time PCR (n = 6, per genotype). PDYNWT and PDYNR212W mice showed equal
transgene expression. Values are mean  SEM. (C) Endogenous Pdyn mRNA levels in the cerebella of 3-month-old PDYNWT, PDYNR212W and
control mice, normalized against 3-month-old control mice revealed by real-time PCR (n = 6, per genotype). Expression of PDYN-wt and PDYN-
R212W did not influence Pdyn mRNA levels. Values are mean  SEM. (D) The quantity mean Pdyn and PDYN mRNA expression. Both PDYNWTand
PDYNR212W mice showed 5-fold increase in total PDYN/Pdyn mRNA expression. Values are mean  SEM. (E) Representative immunoblot image
of PDYN protein levels in cerebella of PDYNWT, PDYNR212W and littermate controls at 3 months of age, stained with anti-C-terminal human PDYN
antibody. For full-length immunoblot see Supplementary Fig. 3. (F) Quantification of PDYN protein levels in 3-month-old mice. Results were
normalized using MemCode staining. PDYNR212W mice showed 1.3-fold decreased PDYN protein levels compared to PDYNWT mice. *P5 0.05,
**P5 0.01. (G) Relative dynorphin A (Dyn A), dynorphin B (DYN B), and Leu-ENK-Arg6 peptide levels in 3-month-old cerebella (n = 2, per
genotype) determined by radioimmunoassay. PDYNWT mice showed a 3.9-fold and 2.4-fold increase in dynorphin A and dynorphin B peptide levels
compared to littermate controls, respectively. Additionally, PDYNR212W mice showed a 11.1- and 2.8-fold increase in dynorphin A and dynorphin B
peptide levels compared to littermate controls, respectively. Notably, a 2.8-fold increase in dynorphin A peptide levels were observed in PDYNR212W
mice compared to age-matched PDYNWT mice. Values are expressed as the percentage of control mice. *P5 0.05, **P5 0.01.
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showed 5-fold elevated PDYN/Pdyn mRNA levels compared
to control mice (Fig. 1D). Despite the equal PDYN/Pdyn
mRNA levels at 3 and 12 months of age, significantly lower
PDYN protein levels were observed in PDYNR212W cerebella
compared to PDYNWT at age 3 and 12 months of age (Fig.
1E, Supplementary Figs 2D and 3). Consistent with lower
PDYN protein levels in cerebellum, PDYN protein levels
were reduced in brain, kidney and liver of PDYNR212W
mice (Supplementary Figs 2C–H and 4). These results
suggest that PDYN-R212W is either more efficiently processed
into peptides or is more rapidly degraded than PDYN-wt.
To examine the processing of PDYN-wt and PDYN-
R212W to dynorphin A, dynorphin B and conversion to
Arg-Leu-enkephalin (Leu-ENK-Arg6), the cerebella of
PDYNWT, PDYNR212W mice and their age-matched controls
were analysed by radioimmunoassay. We observed that
PDYN expression resulted in marked increased levels of
dynorphin A and dynorphin B in the cerebella of
PDYNWT and PDYNR212W mice, compared to littermate
controls at 3 and 12 months of age (Fig. 1G and
Supplementary Fig. 2K). Especially, significantly increased
dynorphin A levels in PDYNR212W mice were observed com-
pared to PDYNWT mice at both 3 and 12 months of age.
This effect was not observed for dynorphin B and Leu-ENK-
Arg6 peptide levels, suggesting that the R212W mutation
selectively alters the processing of PDYN to dynorphin A.
Consistent with clear cerebellar PDYN protein expression
on western blot, strong and specific PDYN and dynorphin
A immunofluorescence signals (in purple) were detected in
the molecular, Purkinje cell and granule cell layers of
PDYNWT and PDYNR212W mice at both age 3 and 12
months (Fig. 2 and Supplementary Fig. 3). These signals
were also observed in the Purkinje cell soma as was
shown by co-localization with the Purkinje cell-specific
marker calbindin (in green), indicating that Purkinje cells
express PDYN and dynorphin A. In general, dynorphin A
localized more to the molecular layer (Fig. 2Q and R) than
PDYN, which showed a more focal localization in the
Purkinje cell soma (Fig. 2H and I).
Taken together, these results show that both transgenic
mouse lines have robust expression of PDYN-wt or PDYN-
R212W in the cerebellum. Despite the low precursor levels,
PDYNR212W mice showed highly elevated (2–3-fold) cere-
bellar mutant dynorphin A levels compared to PDYNWT
mice. These results are in line with our previous data that
showed that the PDYN R212W mutation led to signifi-
cantly enhanced dynorphin A peptide levels in cell models
(Bakalkin et al., 2010), which is likely to be a direct con-
sequence of enhanced PDYN-R212W processing.
Expression of PDYN-R212W causes
Purkinje cell death and loss of climb-
ing fibre–Purkinje cell innervation
To investigate whether PDYN-wt or PDYN-R212W
expression causes cerebellar pathology, we performed a
toluidine blue staining to study the gross morphology of
the cerebellum. The cerebella of both PDYNWT and
PDYNR212W mice did not show any major abnormalities
and were of similar size as littermate controls at 3 and 12
months of age, including the molecular layer
(Supplementary Fig. 4A–G). However, lobule II did show
significant thinning in 12-month-old PDYNR212W mice
(Supplementary Fig. 4G) and a more detailed analysis
revealed significantly marked Purkinje cell loss in the
vermal lobules II, III, VI and in the hemispheric regions
Sim/Crus of 12-month-old PDYNR12W mice compared to
both PDYNWT mice and littermate controls (Fig. 3A). This
was not observed at 3 months of age (data not shown). The
age-dependent Purkinje cell pathology was confirmed by
calbindin immunostainings and Sevier-Munger stainings.
Purkinje cells of 12-month-old PDYNR212W mice showed
mild atrophy of the dendritic tree and loss of Calbindin
staining (Fig. 3B–D). Additionally, Sevier-Munger stainings
demonstrated several stages of Purkinje cell damage in
PDYNR212W mice, including rare axonal torpedoes
(Fig. 3E), single and multiple empty baskets (Fig. 3F and
G), and chronic Purkinje cell loss indicated by the absence
of normal Purkinje cell layer structure (Purkinje cells and
basket cells) (Fig. 3H). In contrast, age-matched PDYNWT
and littermate control cerebella only very rarely displayed a
single empty basket, which was most likely the result of
normal ageing (data not shown). Larger stretches with
empty baskets or areas with chronic Purkinje cell loss
were never observed. No Purkinje cell layer pathology
was observed in 3-month-old PDYNR212W mice (data not
shown), suggesting degeneration occurs relatively late and
progresses slowly, mirroring the human disease (Verbeek
et al., 2004).
Next, we analysed the Purkinje cell pathology more pre-
cisely by examining climbing fibre–Purkinje cell synapses,
using vGlut2 as a marker (Fremeau et al., 2001). Altered
distribution of climbing fibre synapses was previously seen
in SCA1 and SCA7 mice (Duvick et al., 2010; Furrer
et al., 2013), reflected by reduced vGlut2/calbindin
ratios along the Purkinje cell dendrites. The Purkinje cell
dendrites of PDYNR212W mice showed a significantly
reduced climbing fibre synapse distribution in the vermal
lobules II, VI and IX, and in the paraflocculus compared
to PDYNR212W mice and littermate controls, respectively
(Fig. 4A and B). These effects were also observed in lob-
ules II, VI, IX, and paraflocculus of 3-month-old
PDYNR212W mice which significantly progressed over
time up to 12 months of age (Fig. 4B). This suggests
that expression of PDYN-R212W caused early changes
in the climbing fibre–Purkinje cell synapses, and that
these changes progress with age and lead to Purkinje
cell degeneration over time. Notably, the loss of climbing
fibre–Purkinje cell synapses is mostly restricted to the an-
terior vermis and lobule VI; regions found to be respon-
sible for motor coordination and balance (Manni and
Petrosini, 2004; Stoodley and Schmahmann, 2010).
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Figure 2 PDYN and dynorphin A expression in cerebellar Purkinje cells of PDYNWT and PDYNR212W mice. Representative
immunofluorescence images of PDYN (A–I, purple) and dynorphin A (Dyn A, J–R, green) in cerebella of 3-month-old control, PDYNWT and
PDYNR212W mice. The Purkinje cell-specific marker calbindin (in green) was used to identify the Purkinje cell soma and dendrites (D–F and M–O,
for PDYN and dynorphin A, respectively) and the overlay (G–I and P–R, for PDYN and dynorphin A, respectively). Both PDYNWT and PDYNR212W
mice showed marked PDYN expression throughout the cerebellum. PDYN expression shows clear co-localization with the Purkinje cell soma,
whereas dynorphin A expression was mainly detected in the molecular layer, and to a lesser extend in the Purkinje cells. No clear difference was
observed in the PDYN and dynorphin A immunofluorescence between PDYNWT and PDYNR212W mice. Micrographs of cerebellar overall
morphology and 20 magnification. Scale bar = 100 mm.
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Figure 3 Loss and atrophy of Purkinje cells in PDYNR212W mice at 12 months of age. (A) Purkinje cells count in the vermal lobules II,
III, IV/V, VI, X, and Sim/Crus, and paraflocculus (PF) in toluidine blue sections of the cerebellum of 12-month-old PDYNWT and PDYNR212W mice
(n = 5–7, per genotype). PDYNR212W mice showed significantly less Purkinje cells in the vermal lobules II, III, and VI, and Sim/Crus compared to
PDYNWT and control mice. PDYNR212W mice showed on average 4.5  0.36, 4.6  0.04, 4.52  0.26 Purkinje cells per 100 mm in the vermal
lobules II, III, and VI, and 5.1  0.22 in Sim/Crus compared to 7.4  0.52, 10.2  0.36, 6.53  0.75, and 5.59  0.27 Purkinje cells per 100 mm in
PDYNWT mice. Data are presented as mean  SEM. *P5 0.05, **P5 0.01, ***P5 0.001, and ****P5 0.0001. (B–D) Representative calbindin
immunofluorescence images from affected vermal regions of the Purkinje cell and molecular layers of cerebellar from 12-month-old control,
PDYNWT and PDYNR212W mice. PDYNR212W mice showed reduced calbindin immunofluorescence and mild dendritic atrophy compared to PDYNWT
and control mice. Scale bar = 100 mm. (E–H) Representative micrographs of Silver-Munger stainings of the Purkinje cell and molecular layer of
12-month-old PDYNR212W mice. The Purkinje cell layer of PDYNR212W mice showed torpedoes (E), empty baskets (F–H), and regions without
empty baskets (G). This pathology was not observed in age-matched PDYNWT and control mice (n = 2–3, per genotype). Scale bars in E = 50mm,
F–H = 100 mm.
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PDYNR212W mice exhibit gait deficits
and motor dysfunction revealing
cerebellar ataxia
To test whether the subtle but significant and progressive
morphological alterations observed above translate into
neurological effects, we assessed gait- and motor perform-
ance over time using footprint pattern analysis and the
accelerating rod test. Footprint patterns were analysed for
differences in hind base width and the overlap of steps
between the front and hind paws, which are characteristic
for ataxia (Manto and Marmolino, 2009). The hind base
Figure 4 Reduced climbing fibre synapses at Purkinje cell dendrites in PDYNR212W mice. The distribution of climbing fibres (CF) and
Purkinje cell (PC) dendritic tree in the vermal lobules II, IV/V, VI, IX, and Sim/Crus, and paraflocculus (PF) was assessed by vGlut2 and calbindin
immunostaining, respectively. (A) Representative confocal images of lobule VI of the cerebella of control, PDYNWT and PDYNR212W mice at 3 and
12 months of age stained with anti-calbindin antibody, and anti-vGlut2 antibody. Three- and 12-month-old control, PDYNWT and PDYNR212W mice
showed a mean relative height of climbing fibre to molecular layer thickness of 0.78  0.02, 0.79  0.01, 0.71  0.02, and 0.79  0.01,
0.78  0.02, and 0.62  0.03, respectively. (B) Quantification of the relative height of vGlut2 staining compared to molecular layer thickness,
represented by calbindin staining, in the lobules II, IV/V,VI, IX, Sim/Crus and parallel fibre in control, PDYNWT and PDYNR212W mice of 3 and 12
months of age (n = 5–7, per genotype). At 3 months of age, PDYNR212W mice already showed significantly reduced climbing fibre–Purkinje cell
synapses in lobules II, VI, IX, and parallel fibre compared to PDYNWT and control mice. In these regions, PDYNR212W mice showed a relative height
of vGlut2 staining compared to molecular layer thickness of 0.71  0.02, 0.72  0.02, 0.60  0.02, and 0.62  0.07 compared to 0.81  0.01,
0.78  0.02, 0.76  0.02, and 0.78  0.02 in age-matched PDYNWT mice. This effect significantly progressed over time in the vermal lobules II
(0.64  0.02, P = 0.006), VI (0.72  0.02, P5 0.0001), and IX (0.60  0.02, P = 0.0173) in PDYNR212W mice but not for the parallel fibre. Data are
normalized to 3-month-old controls and presented as mean  SEM. *P5 0.05, **P5 0.01, ***P5 0.001, and ****P5 0.0001.
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width of PDYNR212W mice was significantly wider than
PDYNWT mice at all ages, and significantly wider than
control mice at 3, 6 and 9 months of age (Fig. 5A).
Already at 3 months of age, PDYNR212W mice also
showed significant loss of step overlap in contrast to
PDYNWT and control mice, which progressively reached
maximal loss of step overlap at 9–12 months of age (Fig.
5B). The performance on the accelerating rod was only
significantly diminished in PDYNR212W mice at 12
months of age compared to littermate controls, as their
time on the rod was markedly reduced (Fig. 5C).
Although 12-month-old PDYNR212W mice performed
worse than age-matched PDYNWT mice, this difference
was not significant.
Altogether, these data show that PDYNR212W mice
exhibit a mild, slowly progressive, impairment of motor
coordination with deficits in balance and step alterations,
reflecting the mild and progressive neurological symptoms
of SCA23 patients.
PDYNR212W mice show altered
expression of opioid and glutamatergic
signalling
To address the consequence of the elevated mutant dynor-
phin A peptide levels on opioid signalling, we studied the
mRNA expression levels of the opioid receptors Oprd1,
Oprk1, and Oprm1. The expression of PDYN-wt and
PDYN-R212W did not affect Oprd1, Oprk1 and Oprm1
mRNA levels in cerebellum at 3 months of age (Fig. 6A),
but at 12 months of age, PDYNWT mice and control mice
showed significantly increased Oprk1 and Oprm1 mRNA
expression levels compared to PDYNR212W mice (Fig. 6A).
Notably, this increase in receptor expression was also
significant over time for the control mice but not for
PDYNWT mice. Thus, PDYN-R212W reduced opioid
receptor expression in the cerebellum at 12 months of
age.
We hypothesized that the abundant mutant dynorphin A
peptides switch to another receptor system as has been
described for elevated wild type dynorphin A levels in a
pain model (Lai et al., 2006). Therefore, we next studied
the mRNA expression levels of components of the gluta-
matergic system over time in cerebellum, including the
NMDA-R subunits Grin1, Grin2a, and Grin2b,
the AMPA-R subunits Gria2 and Gria3, as dynorphin
A-induced cell death in cell models was previously shown
to be mediated via both NMDA-Rs (Tan-No et al., 2001)
and AMPA-Rs (Singh et al., 2003). No significant differ-
ences were detected for Grin1 and Grin2b mRNA levels
between the different genotypes and time points.
However, a significant increase in Grin2a expression was
observed in 3-month-old PDYNR212W mice compared to
PDYNWT and littermate controls, but not at 12 months
of age (Fig. 6B). Gria2 and Gria3 mRNA levels were iden-
tical for all genotypes at age 3 months, but the trend in
age-dependent decline (not significant) in Gria2 and Gria3
expression in controls and PDYNWT mice was significantly
prevented in PDYNR212W mice (Fig. 6C). We lastly exam-
ined the expression of glutamate transporters Slc1a3,
Slc1a1 and Slc1a6. At 3 months, only Slc1a1 mRNA
levels were significantly elevated in PDYNR212W mice
compared to control mice (Fig. 6D). Whereas a significant
increase in Slc1a3 expression was seen in 12-month-
old PDYNR212W mice compared to PDYNWT mice and
littermate controls (Fig. 6D). These changes in the
mRNA levels of components of the glutamatergic system
imply that expression of PDYN-R212W affects the glutam-
ate system.
Overall, these results indicate that the elevated mutant
dynorphin A levels likely add to disturbed opioid and glu-
tamatergic signalling in the cerebellum and subsequently
contributes to SCA pathogenesis.
Increased expression of PDYN-
R212W causes electrophysiological
changes in cultured cerebellar
neurons
To determine whether expression of PDYN-R212W causes
altered neuronal excitability in the cerebellum, we per-
formed electrophysiological experiments on cultured cere-
bellar neurons from P5 control, PDYNWT and PDYNR212W
pups. As shown in Supplementary Fig. 7, PDYNWT and
PDYNR212W cultures expressed PDYN at similar levels
(Supplementary Fig. 7E–L), whereas control cultures only
showed background staining (Supplementary Fig. 7A–D).
All cultures expressed dynorphin A, with the lowest levels
in control neurons and the highest levels in PDYNR212W
neurons (Supplementary Fig. 7M–X), similar to mice at 3
and 12 months of age. No significant morphological differ-
ences were observed between the genotypes (data not
shown). The cultured neurons were analysed at 10 days
in vitro by whole cell patching, and whole cell currents
were compared. We showed that PDYNR212W cerebellar
neurons exhibit similar expression of voltage-dependent
membrane currents (IV curve) compared to PDYNWT cere-
bellar neurons (Fig. 7A). Additionally, both PDYNWT and
PDYNR212W cerebellar neurons showed significantly smal-
ler Na+ and K+ currents than cerebellar neurons from
control littermates. This suggests that overexpression of
PDYN already has an effect on the physiological function-
ing of the cell.
Current clamp recordings showed that control cerebellar
neurons were characterized by fast spike action potentials
with an amplitude of 61.8  3.1mV and a half-width of
2.6  0.3ms (Fig. 7B). PDYNWT neurons displayed typical
granule cell action potentials (Huang et al., 1993) with a
fast spike amplitude of 66.9  3.1mV and a half-width of
2  0.1ms (Fig. 7C). The activity in PDYNR212W cerebellar
neurons was different from the other genotypes, in that the
amplitude of the spikelets was much smaller,
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37.2  2.4mV (Fig. 7D), and the membrane did not reach
0mV. Furthermore, these spikelets had a half-width of
9.7  1.1ms (Fig. 7D). Additionally, PDYNR212W cerebel-
lar neurons displayed another action potential waveform,
which can be described as a small excitatory post synaptic
potential that did not progress into an action potential (Fig.
7E). Taken together, these results suggest that increased
expression of PDYN impairs cell functioning leading to
reduced Na+ and K+ currents. Furthermore, expression
of PDYN-R212W causes a significant change in the
action potential waveform of cultured PDYNR212W cerebel-
lar neurons affecting neuronal excitability.
Discussion
In this study, we generated the first mouse model for
SCA23 and shown that mice expressing PDYN-R212W re-
capitulate many characteristics of the human phenotype of
SCA23 (Verbeek et al., 2004). PDYNR212W mice develop
mild, slowly progressing ataxia, with subtle gait abnormal-
ities detected at 3 months of age, and an overall decline in
motor performance at 12 months of age, related to synaptic
alterations in Purkinje cells (early) and Purkinje cell loss
(later), coinciding with elevated mutant dynorphin A pep-
tide levels. The loss of climbing fibre–Purkinje cell synapses
most likely contributes to the early motor deficits in
PDYNR212W mice, by causing Purkinje cell malfunctioning
and eventually cell death. The observation that the climbing
fibre retraction is progressive, suggests that loss of climbing
fibre–Purkinje cell synapses is caused by active elimination,
rather than by a developmental issue (Ebner et al., 2013).
Additionally, loss of climbing fibre–Purkinje cell synapses
seems to be common in SCA pathology including SCA1,
SCA7 and SCA14 (Duvick et al., 2010; Shuvaev et al.,
2011; Furrer et al., 2013). However, the relative mild path-
ology of the PDYNR212W mice correlates more with the
conventional (non-polyglutamine) SCA5 mouse model,
which displayed Purkinje cell loss from 6 months of age
(Perkins et al., 2010). The region most affected by neuro-
degeneration was the anterior vermis, a region known to be
involved in motor coordination and balance (Manni and
Petrosini, 2004; Stoodley and Schmahmann, 2010), again
mimicking the human disease (Verbeek et al., 2004).
The question remains why PDYNR212Wmice show rela-
tively restricted cerebellar pathology. We hypothesize that
mutant dynorphin A is mimicking the actions of glutamate,
and selectively targets NMDA receptors comprised of
NR2A and NR2B subunits instead of its native opioid
receptors. These NMDA receptors mainly mediate
Figure 5 PDYNR212W mice exhibit gait abnormalities and
motor dysfunction. (A) Foot print pattern analysis of hind limb
base with in control, PDYNWT and PDYNR212W mice at 3, 6, 9 and 12
months of age (n = 6, per transgenic line and n = 12 for controls).
PDYNR212W mice showed a significantly wider hind limb base
(3.67  0.11) than PDYNWT (2.67  0.04) and control mice
(3.35  0.07) at 3 months of age. This effect persisted up to 12
months of age, where PDYNR212W mice showed a hind limb base
with of 2.77  0.08 compared to 2.33  0.05 and 2.66  0.05 in
age-matched PDYNWTand control mice, respectively. Students t-test,
*P5 0.05, and ***P5 0.001, ****P5 0.0001, and *****P5 0.00001.
(B) Foot print pattern analysis of the overlap of front and hind paw
footprints in control, PDYNWTand PDYNR212W mice at 3, 6, 9, and 12
months of age (n = 6, per transgenic line and n = 12 for controls).
Perfect step overlap equals a score of 0. Significant loss of step
overlap in PDYNR212W mice (0.33  0.1) was observed starting at 3
months of age compared to PDYNWT (0.11  0.06) and control
mice (0  0.06). This deficit progressed with aging up to 9 months
of age (range 0.33–1.15  0.10). Loss of step overlap was not
observed in PDYNWT mice or littermate controls. One-way
ANOVA, **P5 0.01, and ***P5 0.001 (C) Quantification of the
latency to fall from the accelerating rotarod performance on ex-
perimental Day 4 of control, PDYNWTand PDYNR212W mice at 3, 6, 9,
and 12 months of age (n = 6, per transgenic line and n = 12 for
controls). Only at 12 months of age PDYNR212W mice showed a
significantly decreased latency to fall compared with similarly aged
Figure 5 Continued
PDYNWT mice and littermate controls. PDYNR212W mice at 12
months of age stayed on average 38.99  2.67 s on the accelerating
rod compared to PDYNWT mice and littermate controls, which
stayed on the rod for 61.32  4.56 and 81.34  5.40 s, respectively.
One-way ANOVA, *P5 0.05.
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excitatory post synaptic potentials on Purkinje cells at
Purkinje cell–climbing fibre synapses (Renzi et al., 2007),
and overactivation may contribute to retraction of climbing
fibres, affecting intracellular calcium concentrations and in-
duction of cerebellar plasticity which plays an important
role in preserving motor performance (Hansel et al.,
2001; Cerminara and Rawson, 2004; Hirano, 2013).
This work confirms our previous genetic and cellular
findings (Bakalkin et al., 2010), and shows that the
R212W mutation in PDYN results in elevated dynorphin
A levels in vivo and causes cerebellar ataxia. The elevated
dynorphin A peptide levels are probably the result of
enhanced PDYN-R212W processing, as low precursor
protein levels were detected in PDYNR212W mice.
Additionally, the R212W mutation may stabilize the
mutant peptide, as unchanged levels of the peptide cleavage
product, Leu-ENK-Arg6, were observed. This suggests that
mutant dynorphin A is degraded less efficiently, leading to
accumulation of mutant dynorphin A, but not dynorphin
B, in the tissue. Additionally, the elevated levels of mutant
dynorphin A are very likely the cause of Purkinje cell death
and cerebellar ataxia.
Previous studies have already shown that dynorphin A
can cause cytotoxicity through various non-opioid mechan-
isms (Hauser et al., 1999; Tan-No et al., 2001; Singh et al.,
2002, 2003; Sherwood and Askwith, 2009). Here, the
Figure 6 Altered expression of opioid receptors and glutamatergic signalling components in cerebella of PDYNR212W mice.
Quantification of RT-PCR data of 3- and 12-month old cerebella of control, PDYNWT and PDYNR212W mice (n = 6, per genotype). All data were
normalized to 3-month-old controls. (A) At 3 months of age, no significant difference was observed between the expression of the opioid
receptors between the three genotypes. At 12 months of age, both PDYNWT and control mice showed significantly increased (2.5-fold each)
Oprk1 and Oprm1 mRNA expression compared to PDYNR212W mice. This increase in receptor mRNA expression over time was only significant
(Oprk1, P5 0.0001 and Oprm1, P5 0.0002) for control mice and not for PDYNWT mice. *P5 0.05, **P5 0.01 and ***P5 0.001. (B) Grin2a
mRNA expression was only significantly increased by 1.7- and 1.6-fold in 3-month-old PDYNR212W mice compared to PDYNWT and control
mice, respectively. This was effect was no longer observed at 12 months of age. No significantly differences were detected in the mRNA
expression of Grin1 and Grin2b between the genotypes or over time. **P5 0.01 and ****P5 0.0001. (C) No significant changes in Gria2 and Gria3
mRNA expression were detected between the various genotypes at 3 months of age. At 12 months, both Gria2 and Gria3 mRNA expression was
significantly increased (Gria2, 1.3-fold and Gria3, 1.4-fold) in PDYNR212W mice compared to PDYNWT and control mice, respectively. However,
this difference in mRNA expression levels was due to a decline in Gria2 and Gria3 mRNA expression in PDYNWT and control mice. *P5 0.05 and
**P5 0.01. (D) Slc1a1 mRNA expression was 1.2-fold increased in 3-month-old PDYNR212W mice, compared to control mice, that was no
longer observed at 12 months of age. However, Slc1a3 mRNA expression was 1.5-fold increased in PDYNR212W mice compared to both PDYNWT
and control mice at 12 months of age. The Slc1a6 mRNA expression levels did not differ between the genotypes, or over time. *P5 0.05.
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increased mRNA levels of the NMDA-R subunit Grin2a,
which is the major contributor of NMDA-R-mediated exci-
totoxicity (Engelhardt et al., 2006), in PDYNR212W mice at
3 months of age make it tantalizing to speculate that
mutant dynorphin A is (over)stimulating NMDA-Rs con-
taining this subunit. Notably, dynorphin A was previously
shown to directly interact with the NMDA-R and potenti-
ates its glutamate currents (Woods et al., 2006). The tem-
poral decrease in mRNA expression of the Grin2a subunit
may be a compensatory mechanism of the cells trying to
decrease the NMDA-R-induced excitatory post synaptic po-
tentials that may be caused by the elevated Grin2a mRNA
levels (Renzi et al., 2007). Additionally, PDYNR212W mice
highly express glutamate transporters and AMPA-R sub-
units at 12 months of age. Increases in glutamate trans-
porters may suggest that Purkinje cells and Bergmann glia
perceive a high concentration of extracellular glutamate
and attempt to clear this from the synaptic cleft. The
changes in the mRNA expression of AMPA-R subunits
may disturb the induction of cerebellar plasticity
(Miyazaki et al., 2010). Additionally, AMPA-R-mediated
excitotoxicity was proposed as the underlying mechanism
of Purkinje cell loss in SCA5 (Perkins et al., 2010).
Another possible mechanism may be increased opioid-
mediated glutamate release, where mutant dynorphin A
interacts with presynaptically located kappa-opioid recep-
tor to induce release of glutamate, thereby indirectly acti-
vating NMDA-Rs (Kuzmin et al., 2013). However, given
the reduced mRNA expression of Oprk1 in PDYNR212W
mice at 12 months of age, and the reduced affinity of
mutant dynorphin A to bind to kappa-opioid receptor (un-
published data), this mechanism seems unlikely.
In addition, evidence is accumulating that dynorphin A-
mediated neurotoxicity may be non-receptor-mediated, as
dynorphin A peptides were shown to interact with mem-
branes, induce membrane leakage, and translocate across
the plasma membrane, which could underlie neuronal cell
death (Marinova et al., 2005; Madani et al., 2011;
Bjo¨rnera˚s et al., 2013). Interestingly, similar mechanisms
have been reported for the cytotoxicity of amyloid-b in
Alzheimer’s disease, where amyloid-b peptides were
shown to activate extrasynaptic NMDA-Rs indirectly, lead-
ing to synaptic loss and/or changes in the permeability of
membranes after inducing pore formations leading to
increased amyloid formation and toxicity in vivo (Lashuel
et al., 2003; Sepulveda et al., 2010; Nagarathinam et al.,
2013; Talantova et al., 2013).
The altered neuronal excitability as indicated by the dis-
tinct change in the amplitude and action potential wave-
form in cultured cerebellar neurons of PDYNR212W mice
compared to PDYNWT and control cerebellar neurons
likely indicate that expression of PDYN-R212W affects
synaptic transmission. The spikelets cause little depolariza-
tion of the membrane, exhibit slow extinction affecting
repolarization, and do not show overshoot fast spikes
like PDYNWT and control neurons, showing resemblance
to an immature phenotype of granule cells (Prestori et al.,
2008). As the cerebellar neurons examined here demon-
strated action potential waveforms attributed to different
cell populations including granule cells (Huang et al.,
1993), the relevance of these results with regard to
Purkinje cell functioning need to be further investigated.
This data complements our hypothesis of that expression
Figure 7 Voltage clamp recordings show loss of action
potential peak in PDYNR212W cultured cerebellar neurons.
(A) Combined Na + and K + IV curves for control, PDYNWT, and
PDYNR212W cultured neurons show significantly less electrical charge
of the membrane of PDYNWT and PDYNR212W neurons than of
control neurons. *P5 0.05, **P5 0.01, ***P5 0.001, and
****P5 0.0001, cross for PDYNWT versus control, triangle for
PDYNR212W versus control. (B–E) Representative action potential
waveforms. Control neuron action potentials consisted of
61.8  3.1 mV and had a half-width of 2.6  0.3 ms (B), PDYNWT
action potentials had a first peak of 66.9  3.1 mV and a half-width
of 2.0  0.1 ms (C), and PDYNR212W neurons showed action po-
tentials consisting of 37.0  2.4 mV and had a half-width of
9.7  1.1 ms (D) and excitatory post synaptic potentials of
6.2  0.4 mV and a half-width of 35.4  4.4 ms (E). Expression of
PDYN-R212W caused changes in the action potential waveform of
cultured PDYNR212W cerebellar neurons, impairing neuronal activity.
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of PDYN-R212W may cause altered synaptic efficiency, as
information transfer at synapses is based upon changes in
membrane polarization. Additionally, this finding could
support the idea that mutant dynorphin A induces mem-
brane leakage by interacting with the membrane and in-
duces pores in the membrane (Marinova et al., 2005;
Madani et al., 2011; Bjo¨rnera˚s et al., 2013), thereby chan-
ging the membrane potential and impeding expression of
action potentials.
In conclusion, the PDYNR212W mouse is the first mouse
model for SCA23, and it recapitulates the symptoms and
cerebellar pathology of patients with SCA23. We show that
the elevated mutant dynorphin A peptide levels are very
likely responsible for the initiation and progression of
SCA23 disease, and cause alterations in climbing fibre-
Purkinje cell synapse function and motor performance.
Although the mechanism by which mutant dynorphin A
causes neurotoxicity is not completely revealed, our results
show that high levels of mutant dynorphin A correlate with
increased expression of glutamate receptors, including
NMDA-R and AMPA-R subunits that may cause intracel-
lular calcium levels to increase, leading to transcriptional
dysregulation and conceivably neurotoxicity (Fig. 8).
However, given the electrophysiological data, non-receptor
mediated neurotoxicity could also underlie the pathology of
SCA23.
Nevertheless, our mouse model provides unique opportu-
nities to study the disease progression of a pure, isolated
spinocerebellar ataxia during chronological ageing in more
detail, because mutant mice develop their symptoms slowly.
Moreover, our model may be of value beyond understand-
ing SCA23 only, as elevated dynorphin A levels have also
been linked to the pathology of Alzheimer’s disease
(Yakovleva et al., 2007), supporting a more general impli-
cation of elevated opioid neuropeptides levels in the aeti-
ology of neurodegenerative disorders.
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